Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 16/20 | 0.68 |
| ▸ | OPRD1 | P41143 | 16/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781527 | 0.94 | OPRD1 (0.67) | OPRM1OPRD1KCNH2 | |
| SCHEMBL5779820 | 0.92 | OPRM1 (0.67) | OPRM1OPRD1KCNH2 | |
| SCHEMBL5779804 | 0.91 | OPRM1 (0.65) | OPRM1OPRD1KCNH2MAPK1SMN1; SMN2 | |
| SCHEMBL5781201 | 0.90 | OPRD1 (0.64) | OPRM1OPRD1KCNH2 | |
| SCHEMBL5779862 | 0.89 | OPRD1 (0.63) | OPRM1OPRD1KCNH2 | |
| SCHEMBL5781369 | 0.89 | OPRD1 (0.61) | OPRM1OPRD1KCNH2 | |
| SCHEMBL6192560 | 0.88 | OPRD1 (0.85) | OPRM1OPRD1KCNH2 | |
| SCHEMBL5779863 | 0.87 | OPRD1 (0.58) | OPRM1OPRD1KCNH2 | |
| SCHEMBL5781253 | 0.86 | OPRD1 (0.59) | OPRM1OPRD1KCNH2 | |
| SCHEMBL5780724 | 0.86 | OPRD1 (0.57) | OPRM1OPRD1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395575-B1 | 4-(PENYL-PIPERIDIN-4-YLIDENE-METHYL)-BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | claimed |
| US-6838468-B2 | 4-(phenyl-piperdin-4-ylidene methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2005-01-04 | — | — | US | claimed |
| US-20040147553-A1 | 4-(phenyl-piperdin-4-ylidene methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | claimed |
| EP-1395575-A1 | 4-(PENYL-PIPERIDIN-4-YLIDENE-METHYL)-BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS | AstraZeneca AB (SE) | 2004-03-10 | — | — | EP | claimed |
| WO-2002094811-A1 | 4-(PENYL-PIPERIDIN-4-YLIDENE-METHYL)-BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2002-11-28 | — | — | WO | claimed |
| EP-1395575-B1 | 4-(PENYL-PIPERIDIN-4-YLIDENE-METHYL)-BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | disclosed |
| US-6967079-B2 | Pyrimidine derivatives for labeled binding partners | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-6838468-B2 | 4-(phenyl-piperdin-4-ylidene methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2005-01-04 | — | — | US | disclosed |
| US-20040147553-A1 | 4-(phenyl-piperdin-4-ylidene methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20030207824-A1 | Pyrimidine derivatives for labeled binding partners | MATTEUCCI MARK D (US) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207824-A1 | Pyrimidine derivatives for labeled binding partners | HNRNPH3, NSUN2, HNRNPH1 | OPRM1 334/4885OPRD1 900/4885KCNH2 1995/4885 |
| US-20040147553-A1 | 4-(phenyl-piperdin-4-ylidene methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | HTR1D, OPRD1, HTR2C | OPRM1 5/4885OPRD1 2/4885KCNH2 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.